Department of Radiation Oncology, NYU Langone Health, New York, New York, USA.
Department of Otolaryngology, NYU Langone Health, New York, New York, USA.
Otolaryngol Head Neck Surg. 2022 Sep;167(3):494-500. doi: 10.1177/01945998211067503. Epub 2021 Dec 28.
Sinonasal cancer often presents as locoregionally advanced disease. National guidelines recommend management of stage T4b tumors with systemic therapy and radiotherapy, but recent studies suggest that including surgical resection in the multimodal treatment of these tumors may improve local control and survival. We queried the National Cancer Database to examine patterns of care and outcomes in T4b sinonasal squamous cell carcinoma (SCC).
Prospectively gathered data.
National Cancer Database.
Patients with T4b N0-3 M0 sinonasal squamous cell carcinoma diagnosed in 2004 to 2016 were stratified between those who received chemoradiotherapy and those who underwent surgical resection with neoadjuvant or adjuvant treatment. The overall survival of each cohort was assessed via Kaplan-Meier analysis and Cox proportional hazard models, with repeat analysis after reweighting of data via inverse probability of treatment weighting.
Among 805 patients included in analysis, 2-year overall survival for patients undergoing surgical resection was 60.8% (95% CI, 56.1%-65.9%), while for patients undergoing chemoradiotherapy it was 46.7% (95% CI, 41.9%-52.0%). On Cox regression analysis, the inclusion of surgery in management was associated with improved survival in univariate analysis (hazard ratio [HR], 0.723 [95% CI, 0.606-0.862]; < .001) and multivariate analysis (HR, 0.739 [95% CI, 0.618-0.885]; = .001). Results with reweighted data were consistent in univariate analysis (HR, 0.765 [95% CI, 0.636-0.920]; = .004]).
Surgical treatment with neoadjuvant or adjuvant treatment for stage T4b sinonasal SCC was associated with promising survival outcomes, suggesting a role for incorporating surgery in treatment of select T4b SCC, particularly when removal of all macroscopic disease is feasible.
鼻窦癌常表现为局部晚期疾病。国家指南建议对 T4b 期肿瘤采用全身治疗和放疗进行治疗,但最近的研究表明,在这些肿瘤的多模式治疗中加入手术切除可能会改善局部控制和生存率。我们查询了国家癌症数据库,以检查 T4b 鼻窦鳞状细胞癌(SCC)的治疗模式和结果。
前瞻性收集数据。
国家癌症数据库。
2004 年至 2016 年间诊断为 T4bN0-3M0 鼻窦鳞状细胞癌的患者分为接受放化疗和接受新辅助或辅助治疗的手术切除组。通过 Kaplan-Meier 分析和 Cox 比例风险模型评估每个队列的总生存率,并通过治疗加权逆概率重复分析数据后进行重复分析。
在纳入分析的 805 名患者中,接受手术切除的患者 2 年总生存率为 60.8%(95%CI,56.1%-65.9%),而接受放化疗的患者为 46.7%(95%CI,41.9%-52.0%)。在 Cox 回归分析中,在单因素分析中,将手术纳入治疗与生存改善相关(风险比[HR],0.723[95%CI,0.606-0.862];<0.001)和多因素分析(HR,0.739[95%CI,0.618-0.885];=0.001)。重新加权数据的单因素分析结果一致(HR,0.765[95%CI,0.636-0.920];=0.004)。
对于 T4b 鼻窦 SCC,采用新辅助或辅助治疗的手术治疗与有希望的生存结果相关,这表明在选择 T4b SCC 时,将手术纳入治疗具有一定作用,特别是当可以切除所有肉眼可见的疾病时。